自拟扶正解毒消积方联合替吉奥胶囊治疗中晚期原发性肝癌疗效观察

摘要

目的 探讨自拟扶正解毒消积方联合替吉奥胶囊治疗中晚期原发性肝癌的疗效.方法 根据治疗方法的不同将98例中晚期原发性肝癌患者分为中药组60例与西药组38例,西药组给予替吉奥胶囊、卡培他滨、奥沙利铂化疗,中药组在西药组基础上给予自拟扶正解毒消积方治疗,2组均以3周为1个周期,治疗4个周期.统计2组近期疗效及毒副反应发生情况,观察2组治疗前后肝功能指标变化情况,随访2组治疗后6个月与1年生存率.结果 中药组治疗总有效率明显高于西药组(P<0.05).治疗期间2组血液毒性反应、肝肾功能异常、消化道反应、神经系统反应发生率比较差异均无统计学意义(P均>0.05).治疗后2组血清ALT与AST水平均明显低于治疗前(P均<0.05),且中药组血清ALT与AST水平均明显低于西药组(P均<0.05).中药组随访6个月与1年生存率均明显高于西药组(P均<0.05).结论 自拟扶正解毒消积方联合替吉奥胶囊治疗中晚期原发性肝癌患者近期疗效好,不增加毒副反应的发生,且可明显改善肝功能,提高生存率.%Objective It is to investigate the clinical effect of Fuzheng Jiedu Xiaoji Recipe(FJXR) combined with Te-gafur,Gimeracil and Oteracil Potassium Capsules (S-1) in the treatment of middle/advanced primary hepatic carcinoma. Methods 98 cases of patients with middle and advanced primary liver cancer were divided into 60 cases of Chinese medi-cine group and 38 cases of western medicine group according to the different treatment methods, the patients were treated with S-1,capecitabine,oxaliplatin in the western medicine group,and were given FJXR on the basis of the western medi-cine group in the Chinese medicine group. There were 3 weeks as 1 cycles,and treated for 4 cycles in the 2 groups. The short-term effect and the occurrence of toxic and side effects were observed in the 2 groups,the changes of liver function in-dexes before and after treatment were observed in the 2 groups,and the 6-month and 1-year survival rates were followed up between the 2 groups. Results The total effective rate of the Chinese medicine group was significantly higher than that of the western medicine group (P<0.05). There was no significant difference in the incidence of hematological toxicity, liver and renal dysfunction,gastrointestinal reaction and nervous system reaction between the 2 groups (all P>0.05). After treatment,the levels of serum ALT and AST in the 2 groups were significantly lower than those before treatment (all P<0.05),and the levels of serum ALT and AST in the Chinese medicine group was significantly lower than those in the west-ern medicine group(all P<0.05). The 6-month and 1-year survival rates of the Chinese medicine group were significantly higher than those in the western medicine group (all P<0.05). Conclusion FJXR combined with S-1 in the treatment of patients with middle/advanced primary hepatic carcinoma is good in short-term curative effect,and it does not increase the occurrence of toxic and side effects,can obviously improve the liver function and increase the survival rate.